论文部分内容阅读
目的 测定原发性肝癌伴肝硬化脾亢患者行肝动脉化疗栓塞 (TAE)加部分脾栓塞 (PSE)与单纯肝动脉化疗栓塞的效果与不良反应。方法 3 6例用TAE +PSE ;3 2例单用TAE。结果 肝动脉化疗栓塞加部分脾栓塞疗效满意。TAE +PSE组放射学证明有效的为 3 3例 ( 91 7% ) ;其中 ,PR 3 2 7% ( 11/3 6) ;单用TAE为 71 8% ,其中PR 2 1 8% ( 7/3 2 )。观察血常规、肝功能及各项免疫指标 ,发现该组血细胞下降较单纯肝动脉化疗栓塞组明显减少 ,两组比较有显著差异 (P <0 0 1) ,肝动脉化疗栓塞加部分脾栓塞组治疗前后肝功能改善也较单纯肝动脉化疗栓塞组明显。结论 肝动脉化疗栓塞加部分脾栓塞对治疗原发性肝癌伴肝硬化脾亢患者有效 ,值得进一步研究。
Objective To determine the efficacy and adverse reactions of transcatheter arterial chemoembolization (TAE) plus partial splenic embolization (PSE) and hepatic arterial chemoembolization in patients with primary liver cancer and cirrhosis of liver. Method 3 6 cases with TAE + PSE; 32 cases with TAE alone. Results Hepatic arterial chemoembolization plus partial splenic embolization was effective. The TAE + PSE group was 33 3 (91.7%) radiologically proven; PR 3 27% (11/3 6); TAE alone 71 8%, PR 2 18% (7 / 3 2). The blood routine, liver function and various immune indexes were observed. The decrease of blood cells in this group was significantly lower than that of the simple hepatic arterial chemoembolization group (P <0.01). The hepatic arterial chemoembolization plus partial splenic embolization group Liver function before and after treatment was also better than that of hepatic arterial chemoembolization group. Conclusion Transcatheter arterial chemoembolization plus partial splenic embolization is effective in the treatment of patients with primary hepatocellular carcinoma and liver cirrhosis hypersplenism and deserves further study.